Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum P 17630
- Development stage
- Phase 2
- Lead developer
- Proge Farm
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal, Oral
01
Overview
Lactobacillus plantarum P 17630 is a live biotherapeutic product (LBP) consisting of a specific probiotic bacterial strain isolated from healthy human vaginal flora. Developed by PROGE FARM, it is designed to restore the healthy lactobacillary balance of the vaginal microflora and inhibit the adhesion of Candida albicans to vaginal epithelial cells. It is indicated for the treatment and prevention of vulvovaginal candidiasis (VVC), including recurrent cases, as well as other vaginal infections like vaginitis and vaginosis. The drug is available in both topical vaginal and oral capsule formulations, with the oral version marketed under the brand name Rosella. Clinical evaluation includes a Phase 2 trial comparing its efficacy to miconazole in pre-menopausal women.
- Brand names
- Rosella
- Other names
- Lactiplantibacillus plantarum PROGE P17630Lactobacillus plantarum P17630
02
Targets
Vaginal microbiota composition and pH
Beyond the preview
Go deeper on lactobacillus plantarum P 17630.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum P 17630.